Monitoring response to disease-modifying treatment in multiple sclerosis
Background: Standard criteria for defining suboptimal response to disease-modifying treatment (DMT) in patients with multiple sclerosis (MS) are lacking. Decision-making on how and when DMTs should be switched is challenging. The objective of the study was to identify areas of agreement on which and...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | Neurology Perspectives |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266704962300011X |
| _version_ | 1797797059558899712 |
|---|---|
| author | J. Río J. Peña L. Brieva J.M. García-Domínguez A. Rodríguez-Antigüedad C. Oreja-Guevara L. Costa-Frossard R. Arroyo |
| author_facet | J. Río J. Peña L. Brieva J.M. García-Domínguez A. Rodríguez-Antigüedad C. Oreja-Guevara L. Costa-Frossard R. Arroyo |
| author_sort | J. Río |
| collection | DOAJ |
| description | Background: Standard criteria for defining suboptimal response to disease-modifying treatment (DMT) in patients with multiple sclerosis (MS) are lacking. Decision-making on how and when DMTs should be switched is challenging. The objective of the study was to identify areas of agreement on which and when specific assessments should be conducted to monitor patient response to DMT. Methods: A survey comprising 54 statements in nine categories was drafted by eight MS experts after gathering insight during four previous meetings of a total of 25 MS experts. For each statement, results were classified as being in general agreement (≥66.6% responded “Strongly agree” or “Agree”) or general disagreement (≥66.6% responded “Strongly disagree” or “Disagree”). Results: The survey was sent to 790 MS neurologists, 151 of whom participated (19%), and 98 (65%) completed it. General agreement and disagreement were reached for 45 and 2 statements, respectively, on different aspects of MS management, including treatment response, MS relapses, progression, disease activity measured by imaging and biomarkers, neuropsychological evaluation, brain volume loss, DMT switches due to lack of response and applicability to clinical practice. Conclusions: This study aims to provide guidance for the early identification of suboptimal response to DMT and for improving MS patient monitoring and treatment. |
| first_indexed | 2024-03-13T03:43:29Z |
| format | Article |
| id | doaj.art-4e3bc48851be41378fddf3c792f03e93 |
| institution | Directory Open Access Journal |
| issn | 2667-0496 |
| language | English |
| last_indexed | 2024-03-13T03:43:29Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurology Perspectives |
| spelling | doaj.art-4e3bc48851be41378fddf3c792f03e932023-06-23T04:44:57ZengElsevierNeurology Perspectives2667-04962023-04-0132100119Monitoring response to disease-modifying treatment in multiple sclerosisJ. Río0J. Peña1L. Brieva2J.M. García-Domínguez3A. Rodríguez-Antigüedad4C. Oreja-Guevara5L. Costa-Frossard6R. Arroyo7Neurology Department, CemCat-Vall d'Hebrón, Barcelona, Spain; Corresponding author.Neurology Department, Hospital Universitario San Agustín, Avilés, SpainNeurology Department, Hospital Universitario Arnau de Vilanova, Lleida, SpainNeurology Department, Hospital Universitario Gregorio Marañón, Madrid, SpainNeurology Department, Hospital Universitario Cruces, Barakaldo, SpainNeurology Department, Hospital Universitario Clínico San Carlos, Madrid, SpainNeurology Department, Hospital Universitario Ramón y Cajal, Madrid, SpainNeurology Department, Hospital Quirón Salud y Ruber, Madrid, SpainBackground: Standard criteria for defining suboptimal response to disease-modifying treatment (DMT) in patients with multiple sclerosis (MS) are lacking. Decision-making on how and when DMTs should be switched is challenging. The objective of the study was to identify areas of agreement on which and when specific assessments should be conducted to monitor patient response to DMT. Methods: A survey comprising 54 statements in nine categories was drafted by eight MS experts after gathering insight during four previous meetings of a total of 25 MS experts. For each statement, results were classified as being in general agreement (≥66.6% responded “Strongly agree” or “Agree”) or general disagreement (≥66.6% responded “Strongly disagree” or “Disagree”). Results: The survey was sent to 790 MS neurologists, 151 of whom participated (19%), and 98 (65%) completed it. General agreement and disagreement were reached for 45 and 2 statements, respectively, on different aspects of MS management, including treatment response, MS relapses, progression, disease activity measured by imaging and biomarkers, neuropsychological evaluation, brain volume loss, DMT switches due to lack of response and applicability to clinical practice. Conclusions: This study aims to provide guidance for the early identification of suboptimal response to DMT and for improving MS patient monitoring and treatment.http://www.sciencedirect.com/science/article/pii/S266704962300011XMultiple sclerosissuboptimal treatment responseMS managementMS treatment |
| spellingShingle | J. Río J. Peña L. Brieva J.M. García-Domínguez A. Rodríguez-Antigüedad C. Oreja-Guevara L. Costa-Frossard R. Arroyo Monitoring response to disease-modifying treatment in multiple sclerosis Neurology Perspectives Multiple sclerosis suboptimal treatment response MS management MS treatment |
| title | Monitoring response to disease-modifying treatment in multiple sclerosis |
| title_full | Monitoring response to disease-modifying treatment in multiple sclerosis |
| title_fullStr | Monitoring response to disease-modifying treatment in multiple sclerosis |
| title_full_unstemmed | Monitoring response to disease-modifying treatment in multiple sclerosis |
| title_short | Monitoring response to disease-modifying treatment in multiple sclerosis |
| title_sort | monitoring response to disease modifying treatment in multiple sclerosis |
| topic | Multiple sclerosis suboptimal treatment response MS management MS treatment |
| url | http://www.sciencedirect.com/science/article/pii/S266704962300011X |
| work_keys_str_mv | AT jrio monitoringresponsetodiseasemodifyingtreatmentinmultiplesclerosis AT jpena monitoringresponsetodiseasemodifyingtreatmentinmultiplesclerosis AT lbrieva monitoringresponsetodiseasemodifyingtreatmentinmultiplesclerosis AT jmgarciadominguez monitoringresponsetodiseasemodifyingtreatmentinmultiplesclerosis AT arodriguezantiguedad monitoringresponsetodiseasemodifyingtreatmentinmultiplesclerosis AT corejaguevara monitoringresponsetodiseasemodifyingtreatmentinmultiplesclerosis AT lcostafrossard monitoringresponsetodiseasemodifyingtreatmentinmultiplesclerosis AT rarroyo monitoringresponsetodiseasemodifyingtreatmentinmultiplesclerosis |